Back to top
more

REGENXBIO (RGNX)

(Delayed Data from NSDQ)

$9.43 USD

9.43
668,980

+0.51 (5.72%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $9.10 -0.33 (-3.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -44.00% and -65.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?

by Zacks Equity Research

Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.

REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Indrajit Bandyopadhyay headshot

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

by Indrajit Bandyopadhyay

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher

by Zacks Equity Research

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

Tirthankar Chakraborty headshot

5 Gene Therapy Stocks to Enrich Your Portfolio

by Tirthankar Chakraborty

Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.

Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3

by Zacks Equity Research

Ultragenyx (RARE) submitts regulatory filings in Canada, Brazil and Colombia for Crysvita for the treatment of XLH.

ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ANIK vs. RGNX: Which Stock Is the Better Value Option?

Implied Volatility Surging for REGENXBIO (RGNX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.

    ALXN vs. RGNX: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    ALXN vs. RGNX: Which Stock Is the Better Value Option?

      ALXN or RGNX: Which Is the Better Value Stock Right Now?

      by Zacks Equity Research

      ALXN vs. RGNX: Which Stock Is the Better Value Option?

        ALXN vs. RGNX: Which Stock Is the Better Value Option?

        by Zacks Equity Research

        ALXN vs. RGNX: Which Stock Is the Better Value Option?

          Sweta Killa headshot

          5 Top Performing Stocks of the Best ETF of 1H2018

          by Sweta Killa

          Inside the top performing stocks of the top ETF of the first half of 2018.

            ALXN vs. RGNX: Which Stock Should Value Investors Buy Now?

            by Zacks Equity Research

            ALXN vs. RGNX: Which Stock Is the Better Value Option?

              REGENXBIO (RGNX) in Focus: Stock Moves 6.2% Higher

              by Zacks Equity Research

              REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

                Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

                by Zacks Equity Research

                Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.

                  BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

                  by Zacks Equity Research

                  BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.

                    What's in the Cards for Merrimack (MACK) in Q3 Earnings?

                    by Zacks Equity Research

                    Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                      What's in the Cards for Repros (RPRX) This Earnings Season?

                      by Zacks Equity Research

                      Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                        Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher

                        by Zacks Equity Research

                        Regenxbio (RGNX) was a big mover last session, as the company saw its shares rise more than 9% on the day.